Dr. Donington on the Role of Neoadjuvant Immunotherapy in Stage II NSCLC

Video

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer. 

Jessica Donington, MD, MSCR, professor of surgery and chief of the Section of Thoracic Surgery at the University of Chicago Medicine, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer (NSCLC).

Trials evaluating neoadjuvant immunotherapy in NSCLC included patients with stage II and stage III disease, says Donington. However, its role in patients with stage II disease is unclear.

It is not standard of care to give patients with stage II disease neoadjuvant chemotherapy prior to surgical resection, explains Donington. Instead, these patients typically undergo resection followed by adjuvant chemotherapy.

Until the field has long-term data with neoadjuvant immunotherapy, patients with stage II disease should continue to undergo up-front surgical resection, concludes Donington.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD